Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
12.74
+0.16 (1.31%)
At close: Apr 28, 2026, 4:00 PM EDT
12.80
+0.07 (0.51%)
After-hours: Apr 28, 2026, 6:07 PM EDT
Amneal Pharmaceuticals Revenue
In the year 2025, Amneal Pharmaceuticals had annual revenue of $3.02B with 8.05% growth. Amneal Pharmaceuticals had revenue of $814.32M in the quarter ending December 31, 2025, with 11.47% growth.
Revenue (ttm)
$3.02B
Revenue Growth
+8.05%
P/S Ratio
1.33
Revenue / Employee
$346,984
Employees
8,700
Market Cap
4.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.02B | 224.80M | 8.05% |
| Dec 31, 2024 | 2.79B | 400.35M | 16.73% |
| Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
| Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
| Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.27B |
| Hims & Hers Health | 2.35B |
| Lantheus Holdings | 1.54B |
| Alkermes | 1.48B |
| Phibro Animal Health | 1.46B |
| Prestige Consumer Healthcare | 1.10B |
| BioCryst Pharmaceuticals | 874.84M |
| Supernus Pharmaceuticals | 718.95M |
AMRX News
- 6 days ago - Amneal Pharmaceuticals Transcript: M&A announcement - Transcripts
- 6 days ago - Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal - Reuters
- 6 days ago - Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader - Business Wire
- 6 days ago - Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance - GlobeNewsWire
- 8 days ago - Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson's Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY® - GlobeNewsWire
- 14 days ago - Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. - GlobeNewsWire
- 19 days ago - Amneal Launches Bimatoprost Ophthalmic Solution, 0.01% - GlobeNewsWire
- 21 days ago - Amneal to Report First Quarter 2026 Results on May 1, 2026 - GlobeNewsWire